Loading clinical trials...
Loading clinical trials...
Concentration of Unbound Cloxacillin in Adults Treated With Continuous Infusion Via Elastomeric Pump
Cloxacillin is the first-line choice for the treatment of severe infections caused by the bacterium Staphylococcus aureus in Sweden. Over the past year, cloxacillin is increasingly administred through continuous infusion. In this study, the free (unbound) concentration of cloxacillin when administered as a continuous infusion will be measured to ensure that the free concentration is neither too high nor too low. A PK/PD model will be developed to predict which dosage of cloxacillin is appropriate for an individual based on age, gender, kidney function, and serum-protein level.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Västmanlands sjukhus Västerås
Västerås, Sweden
Start Date
January 14, 2026
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2027
Last Updated
February 17, 2026
25
ESTIMATED participants
Unbound cloxacillin concentration
DIAGNOSTIC_TEST
Lead Sponsor
Emeli Månsson
Collaborators
NCT05899140
NCT02694458
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00631566